Red Light Holland closes on its majority ownership in Acadian Exotic Mushrooms, now holding a 51% interest.
Mydecine Innovations Group Announces MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial
Mydecine and Johns Hopkins plan a "seamless" (combined) Phase II/III clinical trial of MYCO-001 to treat nicotine addiction.
The Economics of Psychedelics
Roughly 8 million people per year are dying preventable deaths because of lack of (legal) access to psychedelic medicine. It's also killing the economy.
The DEA Proves It Must Be Immediately Abolished
The DEA fights to keep psychedelic drugs illegal while it admits these drugs have valuable medical uses. Meanwhile, Americans are dying every day from lack of legal access.
MINDCURE Announces Financial Results for Fiscal 2021
MINDCURE reports a net loss for the fiscal year of CAD$10.2 million as it prepares to deploy its iSTRYM digital therapeutics platform. Cash and equivalents of CAD$18.3 million.
Red Light Closes Acquisition of Mera Life Sciences and Files Quarterly Financial Statements
Red Light Holland reports its Q1 for fiscal year 2022. The company also confirms closing on its acquisition of Mera Life Sciences.
Psychedelic Drug Industry Report Card For 2021
As investors look to fine-tune their portfolios after the summer, we review the psychedelic drug industry and public company performance in 2021.
MINDCURE Reaches Milestone, Releasing First of its Kind Mental Health Digital Therapeutics Platform to Partner Clinics in North America
MINDCURE has released the initial version of its iSTRYM digital therapeutics platform and expects to begin full commercial deployment in Q1 of 2022.
A World Without Addiction? The Potential of Psychedelic Medicine
Psychedelic drugs are demonstrating unique anti-addiction properties in clinical studies, in a world where over 1 billion people have substance abuse issues.
MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders
MindMed and Forian will collaborate on drug R&D via the real-world evidence (RWE) pathway to drug development.
Psychedelic Medicine: The Legal Disconnect Grows
Two billion treatable (but untreated) mental health disorders globally. Eight million preventable deaths per year. The medicines that can save these lives are still illegal.
Cybin Files Two Additional International Patent Applications in Support of the Company’s Research Phase Programs
Cybin files two new patent applications in support of its proprietary psychedelic compounds.
